69.125High68.450Low45.56KVolume68.450Open68.600Pre Close3.13MTurnover0.44%Turnover Ratio--P/E (Static)10.40MShares69.52552wk High--P/B713.75MFloat Cap54.77352wk Low1.00Dividend TTM10.40MShs Float69.525Historical High1.46%Div YieldTTM0.98%Amplitude21.547Historical Low68.678Avg Price1Lot Size
$Invesco Pharmaceuticals ETF(PJP.US)$ $Ishares Trust U.S. Pharmaceuticals Etf(IHE.US)$ $Spdr Series Trust Spdr S&P Pharmaceuticals Etf(XPH.US)$
$SPDR S&P Biotech ETF(XBI.US)$ $VanEck Biotech ETF(BBH.US)$
Are you looking at a specific industry/market/asset type? Why?
What is your latest fund investment plan? What are the reasons behind it?
The current macro conditions (high inflation, FED rate hike and recession) have crippled our will to invest in long term. In my previous post, I reveal plan to invest in long term to position myself when the economy recover hopefully by ...
$AbbVie(ABBV.US)$: AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022
$Protagonist Therapeutics(PTGX.US)$: Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
$PTC Therapeutics(PTCT.US)$: Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022
$Scholar Rock(SRRK.US)$: Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy
Follow for more insights and top news for pharmacy industry!
No comment yet